Suloctidil

Suloctidil
Clinical data
ATC code	C04AX19 (WHO) ;
Identifiers
	IUPAC name 1-[4-(isopropylthio)phenyl]-2-(octylamino)propan-1-ol;
CAS Number	54767-75-8 ;
PubChem CID	5354;
ChemSpider	571402;
UNII	XV1N1XY17K;
ChEBI	CHEBI:233445;
ChEMBL	ChEMBL588119;
CompTox Dashboard (EPA)	DTXSID701017974 DTXSID4045638, DTXSID701017974 ;
ECHA InfoCard	100.053.920
Chemical and physical data
Formula	C20H35NOS
Molar mass	337.57 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCCCCNC(C)C(C1=CC=C(C=C1)SC(C)C)O;
	InChI InChI=1S/C20H35NOS/c1-5-6-7-8-9-10-15-21-17(4)20(22)18-11-13-19(14-12-18)23-16(2)3/h11-14,16-17,20-22H,5-10,15H2,1-4H3; Key:BFCDFTHTSVTWOG-UHFFFAOYSA-N;
	(verify)

Suloctidil was a sulfur-containing aminoalcohol that was brought to market in the early 1970s as a vasodilator by Continental Pharma, a Belgian company.

Continental was bought by Monsanto in 1984, primarily on the promise of sales of suloctidil, which was approved in Europe at the time, but not in the US. However, in 1985 Monsanto halted development and withdrew the drug worldwide following reports of liver toxicity.